Evidence map›Paper›PMID 25226393›Full record

ArticlePloS one2014

Detection of serum antibodies cross-reacting with Mycobacterium avium subspecies paratuberculosis and beta-cell antigen zinc transporter 8 homologous peptides in patients with high-risk proliferative diabetic retinopathy.

Antonio Pinna, Speranza Masala, Francesco Blasetti, Irene Maiore, Davide Cossu, Daniela Paccagnini, Giuseppe Mameli, Leonardo A Sechi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Neglected Facts onInternational journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Molecular biology research communications · 2017
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Antonio PinnaDepartment of Surgical, Microsurgical and Medical Sciences, Section of Ophthalmology, University of Sassari, Sassari, Italy; Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy.
Speranza MasalaDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy.
Francesco BlasettiDepartment of Surgical, Microsurgical and Medical Sciences, Section of Ophthalmology, University of Sassari, Sassari, Italy.
Irene MaioreDepartment of Surgical, Microsurgical and Medical Sciences, Section of Ophthalmology, University of Sassari, Sassari, Italy.
Davide CossuDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy.
Daniela PaccagniniDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy.
Giuseppe MameliDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy.
Leonardo A SechiDepartment of Biomedical Sciences, Section of Experimental and Clinical Microbiology, University of Sassari, Sassari, Italy.
University of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMAP3865c, a Mycobacterium avium subspecies paratuberculosis (MAP) cell membrane protein, has a relevant sequence homology with zinc transporter 8 (ZnT8), a beta-cell membrane protein involved in Zn++ transportation. Recently, antibodies recognizing MAP3865c epitopes have been shown to cross-react with ZnT8 in type 1 diabetes patients. The purpose of this study was to detect antibodies against MAP3865c peptides in patients with high-risk proliferative diabetic retinopathy and speculate on whether they may somehow be involved in the pathogenesis of this severe retinal disorder.

methodsBlood samples were obtained from 62 type 1 and 80 type 2 diabetes patients with high-risk proliferative diabetic retinopathy and 81 healthy controls. Antibodies against 6 highly immunogenic MAP3865c peptides were detected by indirect ELISA.

resultsType 1 diabetes patients had significantly higher rates of positive antibodies than controls. Conversely, no statistically significant differences were found between type 2 diabetes patients and controls. After categorization of type 1 diabetes patients into two groups, one with positive, the other with negative antibodies, we found that they had similar mean visual acuity (∼ 0.6) and identical rates of vitreous hemorrhage (28.6%). Conversely, Hashimoto's thyroiditis prevalence was 4/13 (30.7%) in the positive antibody group and 1/49 (2%) in the negative antibody group, a statistically significant difference (P = 0.016).

conclusionsThis study confirmed that type 1 diabetes patients have significantly higher rates of positive antibodies against MAP/ZnT8 peptides, but failed to find a correlation between the presence of these antibodies and the severity degree of high-risk proliferative diabetic retinopathy. The significantly higher prevalence of Hashimoto's disease among type 1 diabetes patients with positive antibodies might suggest a possible common environmental trigger for these conditions.

Indexed as

AdolescentAdultAgedAntibodies, BacterialCase-Control StudiesCation Transport ProteinsChildChild, PreschoolCross ReactionsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyEpitopesFemaleHumansInfantAntibodies, BacterialCation Transport ProteinsEpitopesPeptidesSLC30A8 protein, humanZinc Transporter 8

Identifiers

PMID25226393
PMCPMC4166466
OpenAlexW1993209004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.